Search - tctmd.com

Displaying 321 - 331 of 331

Sort: Relevancy | Date

Presentation ACVS 2012

Interventional Treatment of HOCM: Overview of Techniques and Results

Presenter: Rajeev Lochan

August 03, 2012

Presentation Fellows 2012

Hypertrophic Cardiomyopathy and Alcohol Septal Ablation

Presenter: Srihari Naidu

April 22, 2012

Presentation TCT 2012

The Mitochondrial Permeability Transition Pore is a Target for Pharmacological Cardioprotection in Human Hypertrophic Cardiomyopathy

Presenter: Paul S. Rees, Sean M. Davidson, Sian E. Harding, Perry M. Elliott, Derek J. Hausenloy, Derek M. Yellon

January 03, 2012

News Daily News

Percutaneous Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Shows Low Mortality

L.A. McKeown

May 27, 2011

Video

» On Record

Better Education and Awareness in Hypertrophic Cardiomyopathy

January 9, 2025

Video

» Live Case

Emory University Hospitals, Atlanta, GA - Transcatheter Myotomy (SESAME) for Hypertrophic Cardiomyopathy

November 7, 2023

BIO

Michelle Kittleson, MD, PhD

Video

» Interview

Updated Cumulative Results of Treatment with Mavacamten from the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients with Obstructive Hypertrophic Cardiomyopathy

May 4, 2022

Video

» Interview

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

May 4, 2022

Video

» Interview

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

April 3, 2022

Partner Content

Managing the Aorta: from Aneurysm Screening to Acute Dissection

May 15, 2018

Advertisement

Interventional Treatment of HOCM: Overview of Techniques and Results

Hypertrophic Cardiomyopathy and Alcohol Septal Ablation

The Mitochondrial Permeability Transition Pore is a Target for Pharmacological Cardioprotection in Human Hypertrophic Cardiomyopathy

Percutaneous Septal Ablation for Hypertrophic Obstructive Cardiomyopathy Shows Low Mortality

Better Education and Awareness in Hypertrophic Cardiomyopathy

Emory University Hospitals, Atlanta, GA - Transcatheter Myotomy (SESAME) for Hypertrophic Cardiomyopathy

Michelle Kittleson, MD, PhD

Updated Cumulative Results of Treatment with Mavacamten from the EXPLORER-LTE Cohort of the MAVA-LTE Study in Patients with Obstructive Hypertrophic Cardiomyopathy

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

Managing the Aorta: from Aneurysm Screening to Acute Dissection

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content